How bad is this news for Novavax? Let's find out. Image source: Getty Images.

Updated COVID-19 vaccines targeting JN.1-lineage omicron variants of the coronavirus are now available in the U.S. for the ...

Novavax Inc.’s stock tumbled 16% early Wednesday after the company said the FDA has placed a clinical hold on its ...

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Novavax, Inc. (“Novavax” or ...

The U.S. Food and Drug Administration has put on hold a trial of Novavax's COVID-influenza and its standalone flu vaccines ...

The so-called clinical hold is due to a single report of nerve damage in a patient who received the combination shot in a ...

Novavax shares tumbled after the Food and Drug Administration put a clinical hold on its testing applications for a combined ...

Novavax’s plans for growth outside of its COVID program have been thrown into chaos after the FDA put the biooharma's flu ...

The clinical hold affects Novavax’s COVID-flu combo and standalone flu vaccines, which were on the cusp of Phase III testing.

Analyst Eric Joseph of J.P. Morgan maintained a Sell rating on Novavax (NVAX – Research Report), retaining the price target of $9.00.

Novavax said a participant enrolled in a mid stage study of the combination vaccine last month reported symptoms of motor ...

The European Commission authorized Novavax's updated COVID-19 vaccine targeting the JN.1 strain of coronavirus in the region, ...